Poolbeg Pharma (AIM: POLB), 'Poolbeg' or the 'Company', a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, provides an update on the strengthening of its intellectual property (IP) position around the lead product, POLB 001, a small molecule immunomodulator for the treatment of severe influenza.
Investors are β¦